Pharmaceutical News

RSS

ACEA Biosciences receives new U. S. Patent for chemical compound screening

ACEA Biosciences, a pioneer in the development of high-performance microelectronic systems for cell-based assays, diagnostics, and pharmaceutical research, is pleased to report the issuance of a new U. S. Patent for chemical compound screening, with important applications in the development of new pharmaceutical products.

17 Feb 2011

Upcoming Bangladeshi mass cholera vaccine program might shed light on strategy effectiveness

TIME reports on an oral cholera vaccination program to kick off on Thursday in Bangladesh that researchers hope will determine how good of a "weapon" the mass vaccination strategy can be "against an old disease".

17 Feb 2011

Patients with high blood pressure can benefit from 'adherence therapy' course

A high proportion of patients with high blood pressure are failing to take their medication properly and would benefit clinically from a course of 'adherence therapy', according to new research from the University of East Anglia.

17 Feb 2011

MedImmune, PDL BioPharma enter definitive agreement to resolve legal patent disputes

PDL BioPharma, Inc. today announced that PDL and MedImmune, LLC have entered into a definitive settlement agreement that resolves all legal disputes between them, including those relating to MedImmune's product Synagis and PDL's patents known as the Queen et al. patents.

17 Feb 2011

Astellas, AVEO enter development, commercialization agreement for tivozanib

Astellas Pharma Inc., a global pharmaceutical company, and AVEO Pharmaceuticals, Inc. today announced that they have entered into a worldwide agreement outside of Asia to develop and commercialize tivozanib, AVEO's lead product candidate designed to optimally block the VEGF pathway by inhibiting all three VEGF receptors, for the treatment of a broad range of cancers.

17 Feb 2011

Inexpensive drug therapy shows promise in treating premature infants with childhood blindness

A readily available, inexpensive drug therapy showed a significant benefit in treating premature infants with the worst and historically most difficult-to-treat cases of retinopathy of prematurity.

17 Feb 2011

Vical announces issuance of U.S. Patent for cytomegalovirus vaccines

Vical Incorporated announced today the issuance of U.S. Patent No. 7,888,112 covering DNA vaccines for cytomegalovirus containing specific gene sequences and formulated with Vical's Vaxfectin adjuvant.

16 Feb 2011

Flu vaccine update

This new vaccine which could become available in the United States in the next few years, is made by growing the influenza virus in cultures of animal cells rather than in the chicken eggs that have been used for more than five decades. This shortens the process by six months. Using animal cells, which are grown in enclosed steel tanks, also reduces the risk of bacterial contamination, which has led to shortages of seasonal vaccines in some years. The study was reported in The Lancet this Tuesday.

16 Feb 2011

New treatment using naltrexone implants can reduce heroin dependency: Study

A new treatment using naltrexone implants could lead to a significant reduction in heroin dependency. According to the researchers responsible for a recent Norwegian study, this should have major implications for the treatment options offered to heroin-dependent patients.

16 Feb 2011

ADVENTRX updates ANX-514 candidate for FDA approval

ADVENTRX Pharmaceuticals, Inc. today provided an update on its product candidate, ANX-514, its polysorbate 80-free formulation of docetaxel.

16 Feb 2011

Bioniche presentation focuses on implementing E. coli cattle vaccine to reduce risk of human infection

Bioniche Life Sciences Inc., a research-based, technology-driven Canadian biopharmaceutical company, gave a presentation about its E. coli O157 cattle vaccine at the First International One Health Congress in Melbourne, Victoria, Australia.

16 Feb 2011

Study: BPS is safe and effective for patients undergoing therapeutic endoscopy

Researchers from Korea report that, compared with conventional sedation, balanced propofol sedation using propofol in combination with midazolam and meperidine, provided higher health care provider satisfaction, better patient cooperation, and similar adverse event profiles in patients undergoing therapeutic endoscopic procedures.

16 Feb 2011

Ecstasy does not impair cognitive performance: Study

Today the journal Addiction published online the results of a neuroscience study finding no evidence of impaired cognitive performance in users of Ecstasy, the street name for the chemical known as MDMA.

16 Feb 2011

CTI's fourth quarter net loss increases to $34.1 million

Cell Therapeutics, Inc. today reported recent accomplishments and financial results for the fourth quarter and year ended December 31, 2010.

16 Feb 2011

Also in global health news: Gates Foundation global health head to step down; drug, medical supply shortages in Gaza; food security in N. Korea

Tachi Yamada, president of the global health program at the Bill & Melinda Gates Foundation, on Monday announced he would step down in June after five years serving in the position, the Associated Press/Seattle Post-Intelligencer reports.

16 Feb 2011

Sanofi-aventis, Sunnybrook enter agreement to develop and commercialize vasculotide

Sanofi-aventis and Sunnybrook Health Sciences Centre announced that they have entered into a research agreement and licensing option for vasculotide, an investigational compound to treat chronic wounds. This includes neuropathic diabetic foot ulcers caused by a lack of sensation and neuropathic ulcers that are complicated by peripheral arterial disease, commonly called neuroischemic diabetic foot ulcers.

16 Feb 2011

New study confirms effectiveness of inhaled epinephrine to treat croup

For more than 30 years, pediatricians have treated children who have croup with inhaled epinephrine to relieve their symptoms quickly. Now, a new review confirms the value of this approach to treat this common respiratory illness, which sometimes turns serious and - in rare instances - can prove fatal.

16 Feb 2011

NGDI-UBC, CDRD partner for drug development platform to treat neglected global diseases

The Centre for Drug Research and Development and the Neglected Global Diseases Initiative at the University of British Columbia today announced that they will collaborate on developing interventions for neglected global diseases and ensuring their delivery to those in need.

16 Feb 2011

Aeolus receives BARDA contract for AEOL 10150 drug development against ARS

Aeolus Pharmaceuticals, a biopharmaceutical company developing a new class of broad spectrum catalytic antioxidant compounds that reduce oxidative stress, inflammation, and subsequent tissue damage-signaling cascades resulting from radiation exposure, today announced that the Biomedical Advanced Research and Development Authority, part of the Department of Health and Human Services, has awarded Aeolus a contract for the advanced development of AEOL 10150 as a medical countermeasure against the pulmonary sub-syndrome of acute radiation syndrome.

16 Feb 2011

Mylan launches generic Vfend

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has launched Voriconazole Tablets, 50 mg and 200 mg, under a previously announced settlement and license agreement with Pfizer Inc. Mylan was the first company to have filed a substantially complete ANDA containing a Paragraph IV certification for Voriconazole Tablets and was awarded 180 days of marketing exclusivity.

16 Feb 2011

Pharmaceutical News

ACEA Biosciences receives new U. S. Patent for chemical compound screening

Upcoming Bangladeshi mass cholera vaccine program might shed light on strategy effectiveness

Patients with high blood pressure can benefit from 'adherence therapy' course

MedImmune, PDL BioPharma enter definitive agreement to resolve legal patent disputes

Astellas, AVEO enter development, commercialization agreement for tivozanib

Inexpensive drug therapy shows promise in treating premature infants with childhood blindness

Vical announces issuance of U.S. Patent for cytomegalovirus vaccines

Flu vaccine update

New treatment using naltrexone implants can reduce heroin dependency: Study

ADVENTRX updates ANX-514 candidate for FDA approval

Bioniche presentation focuses on implementing E. coli cattle vaccine to reduce risk of human infection

Study: BPS is safe and effective for patients undergoing therapeutic endoscopy

Ecstasy does not impair cognitive performance: Study

CTI's fourth quarter net loss increases to $34.1 million

Also in global health news: Gates Foundation global health head to step down; drug, medical supply shortages in Gaza; food security in N. Korea

Sanofi-aventis, Sunnybrook enter agreement to develop and commercialize vasculotide

New study confirms effectiveness of inhaled epinephrine to treat croup

NGDI-UBC, CDRD partner for drug development platform to treat neglected global diseases

Aeolus receives BARDA contract for AEOL 10150 drug development against ARS

Mylan launches generic Vfend

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News